These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31619215)

  • 1. PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study.
    Rodríguez Antolín A; Martínez-Piñeiro L; Jiménez Romero ME; García Ramos JB; López Bellido D; Muñoz Del Toro J; García García-Porrero A; Gómez Veiga F
    BMC Urol; 2019 Oct; 19(1):92. PubMed ID: 31619215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
    Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
    Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
    Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
    Sternberg CN; Molina A; North S; Mainwaring P; Fizazi K; Hao Y; Rothman M; Gagnon DD; Kheoh T; Haqq CM; Cleeland C; de Bono JS; Scher HI
    Ann Oncol; 2013 Apr; 24(4):1017-25. PubMed ID: 23152362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score.
    Oyenuga M; Halabi S; Oyenuga A; McSweeney S; Morgans AK; Ryan CJ; Prizment A
    Prostate; 2023 May; 83(7):688-694. PubMed ID: 36842158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer.
    Shore ND; Tutrone RF; Mariados NF; Nordquist LT; Mehlhaff BA; Steere KJ; Harrelson SS
    Clin Genitourin Cancer; 2018 Apr; 16(2):149-154. PubMed ID: 29196208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
    Boegemann M; Khaksar S; Bera G; Birtle A; Dopchie C; Dourthe LM; Everaert E; Hatzinger M; Hercher D; Hilgers W; Matus G; Alvarez LG; Antoni L; Lukac M; Pissart G; Robinson P; Elliott T
    BMC Cancer; 2019 Jan; 19(1):60. PubMed ID: 30642291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of frailty in modifying physical function and quality of life over time in older men with metastatic castration-resistant prostate cancer.
    Kim VS; Yang H; Timilshina N; Breunis H; Emmenegger U; Gregg R; Hansen AR; Tomlinson G; Alibhai SMH
    J Geriatr Oncol; 2023 Mar; 14(2):101417. PubMed ID: 36682218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
    Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
    BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
    Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
    Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
    Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
    Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS
    Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study.
    Thiery-Vuillemin A; Hvid Poulsen M; Lagneau E; Ploussard G; Birtle A; Dourthe LM; Beal-Ardisson D; Pintus E; Trepiakas R; Antoni L; Lukac M; Van Sanden S; Pissart G; Reid A
    ESMO Open; 2018; 3(5):e000397. PubMed ID: 30116592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional 'QoLiTime' study.
    Hofheinz RD; Lange C; Ecke T; Kloss S; Linsse B; Windemuth-Kieselbach C; Hammerer P; Al-Batran SE
    BJU Int; 2017 May; 119(5):731-740. PubMed ID: 27618249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of treatment on elder-relevant physical function and quality of life outcomes in older adults with metastatic castration-resistant prostate cancer.
    Yang H; Kim VS; Timilshina N; Breunis H; Emmenegger U; Gregg R; Hansen A; Tomlinson G; Alibhai SMH
    J Geriatr Oncol; 2023 Jan; 14(1):101395. PubMed ID: 36988103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
    Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
    Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Descriptive study on burden and communication of fatigue among castration-resistant prostate cancer patients in Japan.
    Iguchi T; Nakamura Y; Akiyama T; Chand K; Yu E
    Curr Med Res Opin; 2022 Mar; 38(3):417-426. PubMed ID: 34918590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
    Smith MR; Rathkopf DE; Mulders PF; Carles J; Van Poppel H; Li J; Kheoh T; Griffin TW; Molina A; Ryan CJ
    J Urol; 2015 Nov; 194(5):1277-84. PubMed ID: 26151676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.